Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 9, 2003, Pages 1043-1053

  Donoghue, Mary ^a   Wakimoto, Hiroko ^b,d   Maguire, Colin T ^b   Acton, Susan ^a   Hales, Paul ^a   Stagliano, Nancy ^a   Fairchild Huntress, Victoria ^a,e   Xu, Jian ^a   Lorenz, John N ^c   Kadambi, Vivek ^a   Berul, Charles I ^b   Breitbart, Roger E ^a,b  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e TUFTS UNIVERSITY   (United States)

Author keywords

ACE2; Connexins; Heart block; Sudden death; Transgenic mice

Indexed keywords

CONNEXIN 40; CONNEXIN 43; DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTROPHYSIOLOGY; GAP JUNCTION; HEART ARRHYTHMIA; HEART BLOCK; HEART CONDUCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE REMODELING; HEART VENTRICLE TACHYCARDIA; INCIDENCE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUDDEN DEATH; SURVIVAL; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

EID: 10744223104     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2828(03)00177-9     Document Type: Article

References (47)

1. Blaufarb I.S., Sonnenblick E.H. The renin-angiotensin system in left ventricular remodeling. Am J Cardiol. 77:1996;8C-16C.
2. Sadoshima J., Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 73:1993;413-423.
3. Kawano H., Do Y.S., Kawano Y., Starnes V., Barr M., Law R.E., et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation. 101:2000;1130-1137.
4. Jongsma H.J. Modulation of gap junction properties in failing hearts. J Cardiovasc Electrophysiol. 10:1999;1421-1424.
5. Saffitz J.E., Laing J.G., Yamada K.A. Connexin expression and turnover: implications for cardiac excitability. Circ Res. 86:2000;723-728.
6. Jongsma H.J., Wilders R. Gap junctions in cardiovascular disease. Circ Res. 86:2000;1193-1197.
7. Urata H., Nishimura H., Ganten D. Chymase-dependent angiotensin II forming systems in humans. Am J Hypertens. 9:1996;277-284.
8. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 275:2000;33238-33243.
9. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 87:2000;E1-E9.
10. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 277:2002;14838-14843.
11. Ferrario C.M., Chappell M.C., Tallant E.A., Brosnihan K.B., Diz D.I. Counterregulatory actions of angiotensin-(1-7). Hypertension. 30:1997;535-541.
12. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 417:2002;822-828.
13. Subramaniam A., Jones W.K., Gulick J., Wert S., Neumann J., Robbins J. Tissue-specific regulation of the α-myosin heavy chain gene promoter in transgenic mice. J Biol Chem. 266:1991;24613-24620.
14. Beddington R.S., Morgernstern J., Land H., Hogan A. An in situ transgenic enzyme marker for the midgestation mouse embryo and the visualization of inner cell mass clones during early organogenesis. Dev Suppl. 106:1989;37-46.
15. Kadowaki H., Kadowaki T., Wondisford F.E., Taylor S.I. Use of polymerase chain reaction catalyzed by Taq DNA polymerase for site-specific mutagenesis. Gene. 76:1989;161-166.
16. Lorenz J.N. A practical guide to evaluating cardiovascular, renal, and pulmonary function in mice. Am J Physiol-Regul Integ Comp Physiol. 282:2002;R1565-R1582.
17. Mitchell G.F., Jeron A., Koren G. Measurement of heart rate and Q-T interval in the conscious mouse. Am J Physiol. 274:1998;H747-H751.
18. Gehrmann J., Hammer P.E., Maguire C.T., Wakimoto H., Triedman J.K., Berul C.I. Phenotypic screening for heart rate variability in the mouse. Am J Physiol Heart Circ Physiol. 279:2000;H733-H740.
19. Berul C.I., Aronovitz M.J., Wang P.J., Mendelsohn M.E. In vivo cardiac electrophysiology studies in the mouse. Circulation. 94:1996;2641-2648.
20. Berul C.I., Maguire C.T., Aronovitz M.J., Greenwood J., Miller C., Gehrmann J., et al. DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model. J Clin Invest. 103:1999;R1-R7.
21. Wakimoto H., Maguire C.T., Kovoor P., Hammer P.E., Gehrmann J., Triedman J.K., et al. Induction of atrial tachycardia and fibrillation in the mouse heart. Cardiovasc Res. 50:2001;463-473.
22. Wakimoto H., Maguire C.T., Sherwood M.C., Vargas M.M., Sarkar P.S., Han J., et al. Characterization of cardiac conduction system abnormalities in mice with targeted disruption of six5 gene. J Interv Card Electrophysiol. 7:2002;127-135.
23. Schlaeger T.M., Bartunkova S., Lawitts J.A., Teichmann G., Risau W., Deutsch U., et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci USA. 94:1997;3058-3063.
24. De Mello W.C. Cell coupling and impulse propagation in the failing heart. J Cardiovasc Electrophysiol. 10:1999;1409-1420.
25. De Mello W.C., Crespo M.J. Correlation between changes in morphology, electrical properties, and angiotensin-converting enzyme activity in the failing heart. Eur J Pharmacol. 378:1999;187-194.
26. De Mello W.C., Cherry R.C., Manivannan S. Electrophysiologic and morphologic abnormalities in the failing heart: effect of enalapril on the electrical properties. J Card Fail. 3:1997;53-61.
27. Dodge S.M., Beardslee M.A., Darrow B.J., Green K.G., Beyer E.C., Saffitz J.E. Effects of angiotensin II on expression of the gap junction channel protein connexin43 in neonatal rat ventricular myocytes. J Am Coll Cardiol. 32:1998;800-807.
28. Guerrero P.A., Schuessler R.B., Davis L.M., Beyer E.C., Johnson C.M., Yamada K.A., et al. Slow ventricular conduction in mice heterozygous for a connexin43 null mutation. J Clin Invest. 99:1997;1991-1998.
29. Thomas S.A., Schuessler R.B., Berul C.I., Beardslee M.A., Beyer E.C., Mendelsohn M.E., et al. Disparate effects of deficient expression of connexin43 on atrial and ventricular conduction: evidence for chamber-specific molecular determinants of conduction. Circulation. 97:1998;686-691.
30. Gutstein D.E., Morley G.E., Tamaddon H., Vaidya D., Schneider M.D., Chen J., et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circulation. 88:2001;333-339.
31. Kirchhoff S., Nelles E., Hagendorff A., Kruger O., Traub O., Willecke K. Reduced cardiac conduction velocity and predisposition to arrhythmias in connexin40-deficient mice. Curr Biol. 8:1998;299-302.
32. Simon A.M., Goodenough D.A., Paul D.L. Mice lacking connexin40 have cardiac conduction abnormalities characteristic of atrioventricular block and bundle branch block. Curr Biol. 8:1998;295-298.
33. Verheule S., van Batenburg C.A., Coenjaerts F.E., Kirchhoff S., Willecke K., Jongsma H.J. Cardiac conduction abnormalities in mice lacking the gap junction protein connexin40. J Cardiovasc Electrophysiol. 10:1999;1380-1389.
34. Bevilacqua L.M., Simon A.M., Maguire C.T., Gehrmann J., Wakimoto H., Paul D.L., et al. A targeted disruption in connexin40 leads to distinct atrioventricular conduction defects. J Intervent Card Electrophysiol. 4:2000;459-467.
35. Mende U., Kagen A., Cohen A., Aramburu J., Schoen F.J., Neer E.J. Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA. 95:1998;13893-13898.
36. Sheridan D.J., Autelitano D.J., Wang B., Percy E., Woodcock E.A., Du X.J. Beta(2)-adrenergic receptor overexpression driven by αMHC promoter is downregulated in hypertrophied and failing myocardium. Cardiovasc Res. 47:2000;133-141.
37. Vos M.A., de Groot S.H., Verduyn S.C., van der Z.J., Leunissen H.D., Cleutjens J.P., et al. Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation. 98:1998;1125-1135.
38. Volders P.G., Sipido K.R., Vos M.A., Kulcsar A., Verduyn S.C., Wellens H.J. Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation. 98:1998;1136-1147.
39. de Groot S.H., Schoenmakers M., Molenschot M.M., Leunissen J.D., Wellens H.J., Vos M.A. Contractile adaptations preserving cardiac output predispose the hypertrophied canine heart to delayed after depolarization-dependent ventricular arrhythmias. Circulation. 102:2000;2145-2151.
40. van Opstal J.M., Verduyn S.C., Leunissen H.D., de Groot S.H., Wellens H.J., Vos M.A. Electrophysiological parameters indicative of sudden cardiac death in the dog with chronic complete AV-block. Cardiovasc Res. 50:2001;354-361.
41. Michaelsson M., Riesenfeld T., Jonzon A. Natural history of congenital complete atrioventricular block. [Review] [32 refs.]. Pacing Clin Electrophysiol. 20:1997;2098-2101.
42. Hein L., Stevens M.E., Barsh G.S., Pratt R.E., Kobilka B.K., Dzau V.J. Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci USA. 94:1997;6391-6396.
43. Redfern C.H., Degtyarev M.Y., Kwa A.T., Salomonis N., Cotte N., Nanevicz T., et al. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. Proc Natl Acad Sci USA. 97:2000;4826-4831.
44. Nakamura K., Robertson M., Liu G., Dickie P., Nakamura K., Guo J.Q., et al. Complete heart block and sudden death in mice overexpressing calreticulin. J Clin Invest. 107:2001;1245-1253.
45. Kasahara H., Wakimoto H., Liu M., Maguire C.T., Converso K.L., Shioi T., et al. Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoprotein. J Clin Invest. 108:2001;189-201.
46. Morley G.E., Vaidya D., Samie F.H., Lo C., Delmar M., Jalife J. Characterization of conduction in the ventricles of normal and heterozygous Cx43 knockout mice using optical mapping. J Cardiovasc Electrophysiol. 10:1999;1361-1375.
47. Kirchhoff S., Kim J.S., Hagendorff A., Thonnissen E., Kruger O., Lamers W.H., et al. Abnormal cardiac conduction and morphogenesis in connexin40 and connexin43 double-deficient mice. Circ Res. 87:2000;399-405.